

We claim:

1. A flowable pharmaceutical composition, comprising: a biocompatible oil and a therapeutically effective amount of a pharmaceutically acceptable salt of an analgesic agent, wherein said salt of said analgesic agent is at most sparingly soluble in said pharmaceutical composition.

*↑
salt of*

2. The flowable pharmaceutical composition of claim 1, wherein said biocompatible oil is a vegetable oil.

3. The flowable pharmaceutical composition of claim 2, wherein said biocompatible oil is one of the following: canola oil, castor oil, coconut oil, corn oil, cottonseed oil, olive oil, palm oil, peanut oil, rapeseed oil, soy bean oil, safflower oil, sesame oil, soybean oil, sunflower oil, and mixtures thereof.

4. The flowable pharmaceutical composition of claim 1, wherein said biocompatible oil is sesame oil.

5. The flowable pharmaceutical composition of claim 1, wherein said biocompatible oil has a viscosity below about 140 cSt at 20 °C.

6. The flowable pharmaceutical composition of claim 1, wherein said pharmaceutical composition has a viscosity below about 90 cSt at 20 °C .

7. The flowable pharmaceutical composition of claim 1, wherein said biocompatible oil has a viscosity above about 45 cSt at 20 °C.

8. The flowable pharmaceutical composition of claim 1, wherein said pharmaceutical composition has a viscosity between about 60 and 90 cSt at 20 °C.

9. The flowable pharmaceutical composition of claim 1, wherein said pharmaceutical composition is flowable at room temperature.

10. The flowable pharmaceutical composition of claim 1, wherein said biocompatible oil has a dielectric constant below about 20.

*Not
know
what
composition
is.*

Sub B1
Cont

11. The flowable pharmaceutical composition of claim 1, wherein said pharmaceutical composition has a dielectric constant below about 20.

12. The flowable pharmaceutical composition of claim 10, wherein said biocompatible oil has a dielectric constant below about 5.

Sub
A2

13. The flowable pharmaceutical composition of claim 1, wherein all biocompatible oils in said flowable pharmaceutical composition comprise at least about 33% by weight of said flowable pharmaceutical composition.

the lack of antecedent basis.

14. The flowable pharmaceutical composition of claim 13, wherein all biocompatible oils in said flowable pharmaceutical composition comprise at least about 50% by weight of said flowable pharmaceutical composition.

15. The flowable pharmaceutical composition of claim 14, wherein all biocompatible oils in said flowable pharmaceutical composition comprise at least about 75% by weight of said flowable pharmaceutical composition.

16. The flowable pharmaceutical composition of claim 14, wherein all biocompatible oils in said flowable pharmaceutical composition is at least about 90% by weight of said flowable pharmaceutical composition.

17. The flowable pharmaceutical composition of claim 1, wherein all biocompatible oils in said flowable pharmaceutical composition comprise at least about 50% by weight of said flowable pharmaceutical composition other than all pharmaceutically acceptable salts of analgesic agents in said pharmaceutical composition.

18. The flowable pharmaceutical composition of claim 17, wherein all biocompatible oils in said flowable pharmaceutical composition comprise at least about 95% by weight of said flowable pharmaceutical composition other than all pharmaceutically acceptable salts of analgesic agents in said pharmaceutical composition.

Sub B1
Cont

19. The flowable pharmaceutical composition of claim 1, wherein said salt of said analgesic agent comprises at least about 2% by weight of said flowable pharmaceutical composition.

Sub B1
Cont

20. The flowable pharmaceutical composition of claim 19, wherein said salt of said analgesic agent comprises at least about 3% and no more than about 80% by weight of said flowable pharmaceutical composition.

Sub
A2

21. The flowable pharmaceutical composition of claim 20, wherein all biocompatible oils in said flowable pharmaceutical composition comprise at least about 50% by weight of said flowable pharmaceutical composition.

Sub B1
Cont

22. The flowable pharmaceutical composition of claim 19, wherein said salt of said analgesic agent comprises at least about 4% and no more than about 67% by weight of said flowable pharmaceutical composition.

Sub
A3

23. The flowable pharmaceutical composition of claim 22, wherein all biocompatible oils in said flowable pharmaceutical composition comprise at least about 70% by weight of said flowable pharmaceutical composition.

24. The flowable pharmaceutical composition of claim 20, wherein said salt of said analgesic agent comprises at least about 10% by weight of said flowable pharmaceutical composition.

25. The flowable pharmaceutical composition of claim 24, wherein said salt of said analgesic agent comprises at least about 40% by weight of said flowable pharmaceutical composition.

Sub B1
Cont

26. The flowable pharmaceutical composition of claim 20, wherein said pharmaceutically acceptable salt of said analgesic agent is an analgesic agent and an inorganic or organic acid addition salt to said analgesic agent.

27. The flowable pharmaceutical composition of claim 1, wherein said analgesic agent is a caine analgesic.

Sub
A4

28. The flowable pharmaceutical composition of claim 27, wherein all biocompatible oils in said flowable pharmaceutical composition comprise at least about 50% by weight of said flowable pharmaceutical composition.

29. The flowable pharmaceutical composition of claim 28, wherein all biocompatible oils in said flowable pharmaceutical composition comprise at least about 85% by weight of said flowable pharmaceutical composition.

30. The flowable pharmaceutical composition of claim 1, wherein said salt of said analgesic agent is a pharmaceutically acceptable salt of lidocaine.

31. The flowable pharmaceutical composition of claim 30, wherein said salt of said analgesic agent is lidocaine HCl.

32. The flowable pharmaceutical composition of claim 31, wherein said biocompatible oil is a vegetable oil.

33. The flowable pharmaceutical composition of claim 31, wherein said biocompatible oil is sesame oil.

34. A kit for treating a disease or condition of a subject, comprising (a) any of the flowable pharmaceutical compositions claimed above, and (b) instructions for combining said biocompatible oil and said salt of said analgesic agent to form a pharmaceutical composition and for administering said flowable pharmaceutical composition to a subject.

35. The kit of claim 34, wherein said disease or condition is pain.

36. The kit of claim 34, wherein said disease or condition is tinnitus.

37. The kit of claim 34, wherein said instructions further provide for parenteral administration of said flowable pharmaceutical composition.

38. The kit of claim 34, wherein said instructions further provide for administration by injection of said flowable pharmaceutical composition.

39. A biocompatible pharmaceutical composition, comprising a biocompatible oil, at least about 2% by weight of a pharmaceutically acceptable salt of an analgesic agent, and no more than 10% by weight of a solvent in which said pharmaceutically acceptable salt of said analgesic agent is at least slightly soluble.

Sub B!
Contd

40. The pharmaceutical composition of claim 39, wherein said solvent comprises no more than 5% by weight of said pharmaceutical composition.

SUB
AC

41. A biocompatible pharmaceutical composition, consisting essentially of a biocompatible oil and at least about 1% by weight of a pharmaceutically acceptable salt of an analgesic agent.

42. A method for treating a disease or condition of a subject, comprising administering parenterally to a subject a pharmaceutical composition comprising (a) a biocompatible oil, and (b) a therapeutically effective amount of a pharmaceutically acceptable salt of an analgesic agent, wherein said salt of said analgesic agent is at most sparingly soluble in said pharmaceutical composition and said pharmaceutical composition is flowable at the body temperature of said subject.

A

43. The method of claim 42, wherein said pharmaceutical composition is administered subcutaneously or intramuscularly.

44. The method of claim 42, wherein said pharmaceutical composition is administered by injection.

45. The method of claim 42, wherein administration of said pharmaceutical composition to a rat results in doubling of a paw withdrawal latency time in a hot plate test for at least about 36 hours.

46. The method of claim 42, wherein administration of said pharmaceutical composition to a rat results in doubling of a paw withdrawal latency time in a hot plate test for at least about 3 days.

47. The method of claims 42, wherein said biocompatible oil has a viscosity allowing said pharmaceutical composition to be administered by injection at room temperature.

48. The method of claim 42, wherein said pharmaceutical composition releases a therapeutically effective amount of said analgesic agent over about at least about 24 hours upon said administration.

49. The method of claim 42, wherein said pharmaceutical composition releases a therapeutically effective amount of said analgesic agent over about at least about four days upon said administration.

50. The method of claim 42, wherein said disease or condition is pain.

51. The method of claim 50, wherein said pain is treated or alleviated for a period of at least about twelve hours after administration of said pharmaceutical composition.

52. The method of claim 50, wherein said pain is treated or alleviated for a period of at least about one day after administration of said pharmaceutical composition.

53. The method of claim 50, wherein said pain is treated or alleviated for a period of at least about three days after administration of said pharmaceutical composition.

54. The method of claim 42, wherein said disease or condition is tinnitus.

55. A method for treating pain in a subject, comprising administering parenterally to a subject a flowable pharmaceutical composition comprising (a) a biocompatible oil, and (b) a pharmaceutically acceptable salt of an analgesic agent, wherein said pharmaceutically acceptable salt of said analgesic agent comprises at least about 2% by weight of said pharmaceutical composition.

56. The method of claim 55, wherein said pharmaceutical composition releases a therapeutically effective amount of said analgesic agent over about at least about 24 hours upon said administration.